Namely, chemotherapy in combination with AKTi could exacerbate the rate of neuropathy to the most extent (SUCRA = 20.9%), followed by anti-PD-L1 antibody (SUCRA = 36.5%) (Figure S7; Table S8). The gene discussed is CD274; the disease is neuropathy.